TW-37
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 1mL(10 mM in DMSO) | ¥850.00 | 现货 | |
| 10mg | ¥993.00 | 现货 | |
| 25mg | ¥2085.00 | 现货 | |
| 50mg | ¥3575.00 | 现货 | |
| 100mg | ¥5177.00 | 现货 |
特色产品
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
产品描述
TW-37是一种有效的BCL-2小分子抑制剂,Ki值为290 nmol/L,衰减BCL-2的活化,抑制多个BCL-2家族成员,包括BCL-XL(Ki = 1,110 nmol/L)和MCL-1(Ki = 260 nmol/L)。TW-37与BCL-2同源结构域3(BH 3)的沟结合,阻止促凋亡蛋白(比如Bid、Bim和Bad)与BCL-2的异二聚化,从而使它们诱导细胞凋亡。最近的研究表明,TW-37能够抑制一系列癌细胞(如乳腺癌、前列腺癌、淋巴瘤和胰腺癌)的生长,TW-37诱导S期细胞周期停滞,调控多个重要的细胞周期相关基因,包括p27、p57、E2F-1、cdc25A、CDK4、cyclin A、cyclin D1和cyclin E。
参考文献:
Zhiwei Wang, Asfar Sohail Azmi, Aamir Ahmad, Sanjeev Banerjee, Shaomeng Wang, Fazlul H. Sarkar, and Ramzi M. Mohammad. TW-37, a small-molecule inhibitor of BCL-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 2009;69:2757-2765
Naoki Ashimori, Benjamin D. Zeitlin, Zhaocheng Zhang, Kristy Warner, IIan M. Turkienicz, Aaron C. Spalding, Theodoros N. Teknos, Shaomeng Wang, and Jacques E. Nor. TW-37, a small-molecule inhibitor of BCL-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther 2009;8:893-903
产品性质
| 物理外观 | Solid |
| CAS号 | 877877-35-5 |
| 分子式 | C33H35NO6S |
| 分子量 | 573.7 |
| 化学名称 | N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide |
| 溶解度 | insoluble in H2O; ≥19.75 mg/mL in DMSO; ≥3.41 mg/mL in EtOH with gentle warming and ultrasonic |
| SMILES | CC(C)C1=CC=CC=C1CC2=C(C(=C(C(=C2)C(=O)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=CC=C4C(C)(C)C)O)O)O |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |
产品应用 (实验数据来自文献,APExBIO并未验证,仅供参考)
IC50和靶点
| 生物活性描述 | TW-37是一种新型的非肽类抑制剂,作用于重组的Bcl-2、Bcl-xL和Mcl-1,Ki值分别为0.29 μM、1.11 μM和0.26 μM。. | ||
| 靶点 | Bcl-2 | Bcl-xL | Mcl-1 |
| 生物活性数据 | 0.29 μM (Ki) | 1.11 μM (Ki) | 0.26 μM (Ki) |
生物相关数据
质量控制
APExBIO 顾客使用本产品发表的 5 篇科研文献
- 1. In-Hyoung Yang, Seung-Hyun Hong, et al. "Cryptotanshinone chemosensitivity potentiation by TW-37 in human oral cancer cell lines by targeting STAT3–Mcl-1 signaling." Cancer Cell Int 2020 Aug 26;20:405. PMID:32863764
- 2. Chi-Hyun Ahn, Won Woo Lee, et al. "Antitumor effect of TW-37, a BH3 mimetic in human oral cancer." Laboratory Animal Research. 04 December 2019.
- 3. Villalobos-Ortiz M, Ryan J, et al. "BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics." Cell Death Differ. 2019 Jul 22. PMID:31332296
- 4. Yang IH, Ahn CH, et al. "Heme Oxygenase-1 is a Key Molecule Underlying Differential Response of TW-37-Induced Apoptosis in Human Mucoepidermoid Carcinoma Cells." Molecules. 2019 May 1;24(9). pii: E1700. PMID:31052354
- 5. Russo M, Milito A, et al. "CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia." Oncotarget. 2017 Jun 27;8(26):42571-42587. PMID:28489572



沪公网安备 31011002003500